---
title: "Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Pharmacodynamics"
description: "Formulary evidence on Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Pharmacodynamics. Topics: Transgene and protein expression: self-complementary compared with single-stranded AAV9 in Rett model cells, Functional comparison of mini-MeCP2 and full-length MeCP2 protein, Genotype-dependent expression attributed to miRARE in Rett model cells, miRARE silencing of transgene expression in cultured cell lines, and 4 further topics. 8 evidence topics quoted from 6 sources."
canonical: "https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/product-information-and-disease-description/pharmacodynamics"
published: "2026-11-15T20:23:41-05:00"
modified: "2026-11-15T20:23:41-05:00"
---

# Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Pharmacodynamics

<a id="heading-2.1.2.6.2"></a>

## 2.1.2.6.2 Pharmacodynamics

<a id="topic-2.1.2.6.2-1"></a>

### Transgene and protein expression: self-complementary compared with single-stranded AAV9 in Rett model cells

> “When looking at MeCP2 expression in RTT model cells, the scAAV9 vector (TSHA-102) produced up to 30-fold more MeCP2 protein than the ssAAV9 vector (ssAAV9-FL-MECP2), which expressed an insignificant amount of MeCP2 protein”
> “Using a GFP model transgene in RTT model cells, scAAV9 expressed ~30-fold more GFP transgene and GFP protein compared with ssAAV9, for which expression was negligible”

Source: [Haque et al. (2026b)](https://tayshagtx.com/wp-content/uploads/ASGCT-Superior-expression-of-self-complementary-AAV-and-comparable-functionality-of-mini-and-full-length-MECP2-support-the-design-of-TSHA-102-gene-therapy-for-Rett-syndrome.pdf)

<a id="topic-2.1.2.6.2-2"></a>

### Functional comparison of mini-MeCP2 and full-length MeCP2 protein

> “mini-MeCP2 and FL-MeCP2 both achieved comparable, stable expression in neuronal cells when transfected with equimolar amounts of plasmid”
> “mini-MeCP2 and FL-MeCP2 proteins showed similar half-lives in the RTT model cells (12 h vs 9 h, respectively; Figure 5A), indicating comparable steady-state abundance and protein synthesis rates”
> “Both proteins inhibited DNMT3 activity in a dose-responsive manner, with similar levels of inhibition observed”

Source: [Haque et al. (2026b)](https://tayshagtx.com/wp-content/uploads/ASGCT-Superior-expression-of-self-complementary-AAV-and-comparable-functionality-of-mini-and-full-length-MECP2-support-the-design-of-TSHA-102-gene-therapy-for-Rett-syndrome.pdf)

<a id="topic-2.1.2.6.2-3"></a>

### Genotype-dependent expression attributed to miRARE in Rett model cells

> “Protein levels were approximately 3.5- to 4-fold higher in RTT model cells compared with WT cells, consistent with miRARE-driven genotypic regulation of expression”
> “Almost no effect on biomolecule dysregulation was observed in WT background (dysregulated 1 and 8 for mini-MeCP2 and FL-MeCP2, respectively), suggesting no off-target activities in WT background as expected due to miRARE”

Source: [Haque et al. (2026b)](https://tayshagtx.com/wp-content/uploads/ASGCT-Superior-expression-of-self-complementary-AAV-and-comparable-functionality-of-mini-and-full-length-MECP2-support-the-design-of-TSHA-102-gene-therapy-for-Rett-syndrome.pdf)

<a id="topic-2.1.2.6.2-4"></a>

### miRARE silencing of transgene expression in cultured cell lines

> “In MECP2–/– 2v6.11 cells, miniMeCP2 protein from the pTSHA102miRARE plasmid accumulated at a mean level ~2.3-fold greater than in parental 2v6.11 cells”
> “A 49% increase in miniMECP2 mRNA”
> “A 197% increase miniMeCP2 protein.”

Source: [Haque et al. (2023)](https://tayshagtx.com/wp-content/uploads/The-microRNA-responsive-autoregulatory-element-from-TSHA-102-for-Rett-Syndrome-modulates-therapeutic-transgene-expression-in-response-to-cellular-MeCP2-in-mouse-and-human-cell-lines.pdf)

<a id="topic-2.1.2.6.2-5"></a>

### Survival, weight, and behavior after intracerebroventricular dosing in neonatal Mecp2 knockout mice

> “TSHA-102-treated KO mice (n=13) survived a median 36.0 weeks, representing a significant (p<0.0001) >4-fold extension of their lifespan versus vehicle-treated KO mice”
> “In WT animals, TSHA-102 treatment showed no toxicity, relative to vehicle treatment.”
> “Onset of severely abnormal gait (e.g., tremor when feet are lifted; backward walking; hopping) was significantly delayed from mean 8 weeks to 20 weeks”

Source: [Okposo et al. (2023)](https://tayshagtx.com/wp-content/uploads/A-Human-ready-Regulated-AAV9miniMECP2-miRARE-Gene-Therapy-TSHA-102-Improves-Survival-Weight-and-Behavior-After-Intracerebroventricular-ICV-Dosing-in-the-Neonatal-Knockout-Rett-RTT-Mouse-Model.pdf)

<a id="topic-2.1.2.6.2-6"></a>

### Efficacy of the human-ready construct in Mecp2 knockout mice

> “In KO mice, TSHA-102 improved respiration, weight, and survival across multiple doses and treatment ages.”
> “Viral genomic DNA and miniMECP2 mRNA were present in the CNS. MiniMeCP2 protein expression was higher in the KO spinal cord compared to the brain.”
> “In female mice, TSHA-102 permitted survivals that were similar to those of vehicle-treated controls.”
> “In all, these pivotal data helped to support the regulatory approval to initiate a clinical trial for TSHA-102 in RTT patients”

Source: [Sadhu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10815157/)

<a id="topic-2.1.2.6.2-7"></a>

### miRARE and the safety of high-dose miniMECP2 gene therapy in Rett mice

> “However, controlling deleterious overexpression of MECP2 remains the critical unmet obstacle towards a safe and effective gene therapy approach for Rett syndrome.”
> “The data provided herein show that insertion of miRARE into the miniMECP2 gene expression cassette greatly improved the safety of miniMECP2 gene transfer without compromising efficacy.”
> “Importantly, this built-in regulation system does not require any additional exogenous drug application, and no miRNAs are expressed from the transgene cassette.”

Source: [Sinnett et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8783608/)

<a id="topic-2.1.2.6.2-8"></a>

### Nonclinical toxicology: single intrathecal dose in rats

> “No TSHA-102 mortality and no adverse TSHA-102-related clinical observations occurred.”
> “Microscopic evaluations (through Day 92) revealed a low incidence of minimal to mild, rarely moderate, axonal degeneration in the sciatic, tibial and sural nerves as well as nerve fibers associated with the DRG in all groups, including the controls.”
> “No apparent TSHA-102 dose association in the incidence or severity of the microscopic changes in the nerves.”
> “At Week 25, there were statistically significant reductions in NCV in mid-dose male and females, and high-dose males compared to control animals (Figure 2A).”

Source: [Prasad et al. (2022b)](https://tayshagtx.com/wp-content/uploads/Safety-Assessment-of-High-Dose-miniMECP2-AAV9-Gene-Replacement-Therapy-TSHA-102-for-Rett-Syndrome-in-Rats.pdf)

## Related pages
- [Lonimecgene renparvovec (TSHA-102): Rett syndrome](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Terms and abbreviations](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/terms-and-abbreviations.md)
- [Lonimecgene renparvovec (TSHA-102): Rett syndrome](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/executive-summary.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Product information and disease description](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/product-information-and-disease-description.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Clinical evidence](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/clinical-evidence.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Economic information and modeling report](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/economics) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/economics.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: References](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/references) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/references.md)
